Skip to main content
Have a personal or library account? Click to login
Myocardial Recovery in Cardiogenic Shock Cover
Open Access
|Aug 2024

References

  1. Tehrani BN, Truesdell AG, Psotka MA, et al. A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock. JACC Heart Fail. 2020 Nov;8(11):879-891. doi: 10.1016/j.jchf.2020.09.005
  2. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024 Apr 18;390(15):1382-1393. doi: 10.1056/NEJMoa2312572
  3. Kapur NK, Kanwar M, Sinha SS, et al. Criteria for Defining Stages of Cardiogenic Shock Severity. J Am Coll Cardiol. 2022 Jul 19;80(3):185-198. doi: 10.1016/j.jacc.2022.04.049
  4. Brusca SB, Caughron H, Njoroge JN, Cheng R, O’Brien CG, Barnett CF. The shock team: a multidisciplinary approach to early patient phenotyping and appropriate care escalation in cardiogenic shock. Curr Opin Cardiol. 2022 May 1;37(3):241-249. doi: 10.1097/HCO.0000000000000967
  5. Alkhunaizi FA, Smith N, Brusca SB, Furfaro D. The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review. CHEST Critical Care. 2024 Jun;2(2). doi: 10.1016/j.chstcc.2024.100071
  6. van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017 Oct 17;136(16):e232-e268. doi: 10.1161/CIR.0000000000000525
  7. Kanwar MK, Selzman CH, Ton VK, et al. Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support. J Heart Lung Transplant. 2022 Oct;41(10):1324-1334. doi: 10.1016/j.healun.2022.05.015
  8. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012 Dec 18;60(24):2465-72. doi: 10.1016/j.jacc.2012.06.062
  9. Wilcox JE, Fonarow GC, Ardehali H, et al. “Targeting the Heart” in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2015 Sep;3(9):661-9. doi: 10.1016/j.jchf.2015.04.011
  10. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2024. Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study; 2023 Jun 8 [cited 2024 Jul 27]. Available at: https://clinicaltrials.gov/study/NCT05291884
  11. Abraham J, Blumer V, Burkhoff D, et al. Heart Failure-Related Cardiogenic Shock: Pathophysiology, Evaluation and Management Considerations: Review of Heart Failure-Related Cardiogenic Shock. J Card Fail. 2021 Oct;27(10):1126-1140. doi: 10.1016/j.cardfail.2021.08.010
  12. Prondzinsky R, Unverzagt S, Lemm H, et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012 May;101(5):375-84. doi: 10.1007/s00392-011-0403-3
  13. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995 Mar 15;91(6):1659-68. doi: 10.1161/01.cir.91.6.1659
  14. Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J. 2012 Mar;33(6):768-75. doi: 10.1093/eurheartj/ehr471
  15. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011 Apr 28;364(17):1607-16. doi: 10.1056/NEJMoa1100356
  16. Perera D, Clayton T, O’Kane PD, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606
  17. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1063-70. doi: 10.1016/s0735-1097(00)00879-2
  18. Kang G, Ha R, Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant. 2016 Jan;35(1):67-73. doi: 10.1016/j.healun.2015.06.009
  19. Jarai R, Fellner B, Haoula D, et al. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med. 2009 Jun;37(6):1837-44. doi: 10.1097/CCM.0b013e31819fe896
  20. Luyt CE, Landivier A, Leprince P, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care. 2012 Oct;27(5):524.e7-14. doi: 10.1016/j.jcrc.2011.12.009
  21. Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Crit Care Med. 2017 Jul;45(7):e666-e673. doi: 10.1097/CCM.0000000000002336
  22. Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Ann Intensive Care. 2017 Dec;7(1):6. doi: 10.1186/s13613-016-0229-2
  23. Takagi K, Blet A, Levy B, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail. 2020 Feb;22(2):279-286. doi: 10.1002/ejhf.1600
  24. Rueda F, Borràs E, García-García C, et al. Protein-based cardiogenic shock patient classifier. Eur Heart J. 2019 Aug 21;40(32):2684-2694. doi: 10.1093/eurheartj/ehz294
  25. Kociol RD, Cooper LT, Fang JC, et al. Recognition and Initial Management of Fulminant Myocarditis. Circulation. 2020 Feb 11;141(6):e69-e92. doi: 10.1161/CIR.0000000000000745
  26. Lupón J, Díez-López C, de Antonio M, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017 Dec;19(12):1615-1623. doi: 10.1002/ejhf.824
  27. Tayal U, Prasad SK. Myocardial remodelling and recovery in dilated cardiomyopathy. JRSM Cardiovasc Dis. 2017 Oct 9:6:2048004017734476. doi: 10.1177/2048004017734476
  28. Marbach JA, Stone S, Schwartz B, et al. Lactate Clearance Is Associated With Improved Survival in Cardiogenic Shock: A Systematic Review and Meta-Analysis of Prognostic Factor Studies. J Card Fail. 2021 Oct;27(10):1082-1089. doi: 10.1016/j.cardfail.2021.08.012
  29. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999 Aug 26;341(9):625-34. doi: 10.1056/NEJM199908263410901
  30. Panza JA, Velazquez EJ, She L, et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol. 2014 Aug 12;64(6):553-61. doi: 10.1016/j.jacc.2014.04.064
  31. Fried JA, Nair A, Takeda K, et al. Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. J Heart Lung Transplant. 2018 Nov;37(11):1313-1321. doi: 10.1016/j.healun.2018.03.011
  32. Thiele H, Zeymer U, Akin I, et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227
  33. Briceno N, Annamalai SK, Reyelt L, et al. Left Ventricular Unloading Increases the Coronary Collateral Flow Index Before Reperfusion and Reduces Infarct Size in a Swine Model of Acute Myocardial Infarction. J Am Heart Assoc. 2019 Nov 19;8(22):e013586. doi: 10.1161/JAHA.119.013586
  34. Swain L, Reyelt L, Bhave S, et al. Transvalvular Ventricular Unloading before Reperfusion in Acute Myocardial Infarction. J Am Coll Cardiol. 2020 Aug 11;76(6):684-699. doi: 10.1016/j.jacc.2020.06.031
  35. Patel SM, Lipinski J, Al-Kindi SG, et al. Simultaneous Venoarterial Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Decompression Therapy with Impella Is Associated with Improved Outcomes in Refractory Cardiogenic Shock. ASAIO J. 2019 Jan;65(1):21-28. doi: 10.1097/MAT.0000000000000767
  36. Ramzy D, Soltesz EG, Silvestry S, Daneshmand M, Kanwar M, D’Alessandro DA. Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patients. J Heart Lung Transplant. 2023 May;42(5):553-557. doi: 10.1016/j.healun.2023.01.011
  37. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; c2024. IMpella-Protected cArdiaC Surgery Trial (IMPACT); 2024 Jun 12 [cited 2024 Jun 27]. Available from: https://clinicaltrials.gov/study/NCT05529654
  38. Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. Circulation. 2017 May 23;135(21):2003-2012. doi: 10.1161/CIRCULATIONAHA.117.028303
  39. Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac Recovery During Long-Term Left Ventricular Assist Device Support. J Am Coll Cardiol. 2016 Oct 4;68(14):1540-53. doi: 10.1016/j.jacc.2016.07.743
  40. Hariri IM, Dardas T, Kanwar M, et al. Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success. J Heart Lung Transplant. 2022 Feb;41(2):161-170. doi: 10.1016/j.healun.2021.07.011
  41. Kittipibul V, Russell S, Milano C, et al. Predictors of Successful Discontinuation of LVAD Support in LVAD-Related Complications and Partial Myocardial Recovery: VAD Wean Registry Analysis. J Heart Lung Transplant. 2024 Apr;43(4):S543-S544. doi: 10.1016/j.healun.2024.02.790
  42. Fida N, Kundi H, Ishaq F, et al. Myocardial Recovery in Contemporary CF-LVADs and Association with Outcomes - A VAD Wean Registry Analysis. J Heart Lung Transplant. 2024 Apr;43(4 Suppl):S545. doi: 10.1016/j.healun.2024.02.793
  43. Tseliou E, Lavine KJ, Wever-Pinzon O, et al. Biology of myocardial recovery in advanced heart failure with long-term mechanical support. J Heart Lung Transplant. 2022 Oct;41(10):1309-1323. doi: 10.1016/j.healun.2022.07.007
  44. Birks EJ, Drakos SG, Patel SR, et al. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020 Nov 24;142(21):2016-2028. doi: 10.1161/CIRCULATIONAHA.120.046415
  45. Itagaki S, Moss N, Toyoda N, et al. Incidence, Outcomes, and Opportunity for Left Ventricular Assist Device Weaning for Myocardial Recovery. JACC Heart Fail. 2024 May;12(5):893-901. doi: 10.1016/j.jchf.2023.12.006
  46. Kolte D, Khera S, Vemulapalli S, et al. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. JACC Cardiovasc Interv. 2018;11(12):1175-1185. doi: 10.1016/j.jcin.2018.03.002
  47. Jung RG, Simard T, Kovach C, et al. Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis. JACC Cardiovasc Interv. 2018 Jun 25;11(12):1175-1185. doi: 10.1016/j.jcin.2018.03.002
  48. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988 Oct;60(4):299-308. doi: 10.1136/hrt.60.4.299
  49. Tran RH, Aldemerdash A, Chang P, et al. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. Pharmacotherapy. 2018 Apr;38(4):406-416. doi: 10.1002/phar.2091
  50. Wirtz HS, Sheer R, Honarpour N, et al. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. J Am Heart Assoc. 2020 Aug 18;9(16):e015042. doi: 10.1161/JAHA.119.015042
  51. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008 Jul 15;52(3):190-9. doi: 10.1016/j.jacc.2008.03.048
  52. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015 Aug;3(8):647-53. doi: 10.1016/j.jchf.2015.03.008
  53. Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc. 2017 Feb 11;6(2):e004675. doi: 10.1161/JAHA.116.004675
  54. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014 Sep 1;114(5):737-42. doi: 10.1016/j.amjcard.2014.05.062
  55. Sohns C, Fox H, Marrouche NF, et al. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023 Oct 12;389(15):1380-1389. doi: 10.1056/NEJMoa2306037
  56. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220. doi: 10.1016/j.jacc.2017.10.054
  57. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007 Jun 13;297(22):2502-14. doi: 10.1001/jama.297.22.2502
  58. Chung MK, Patton KK, Lau C, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. J Arrhythm. 2023 Aug 2;39(5):681-756. doi: 10.1002/joa3.12872
  59. Kirschenbaum LA, Astiz ME, Rackow EC, Saha DC, Lin R. Microvascular response in patients with cardiogenic shock. Crit Care Med. 2000 May;28(5):1290-4. doi: 10.1097/00003246-200005000-00005
  60. De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J. 2004 Jan;147(1):91-9. doi: 10.1016/j.ahj.2003.07.006
  61. den Uil CA, Lagrand WK, van der Ent M, et al. Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2010 Dec;31(24):3032-9. doi: 10.1093/eurheartj/ehq324
  62. Wijntjens GW, Fengler K, Fuernau G, et al. Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy. Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(2):108-119. doi: 10.1177/2048872619870035
  63. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci. 2005 Jun:1047:248-58. doi: 10.1196/annals.1341.022
  64. Stone GW, Martin JL, de Boer MJ, et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv. 2009 Oct;2(5):366-75. doi: 10.1161/CIRCINTERVENTIONS.108.840066
  65. Swain L, Bhave S, Qiao X, et al. Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation. Circulation. 2024 Apr 23;149(17):1341-1353. doi: 10.1161/CIRCULATIONAHA.123.065298
  66. Li H, Bao M, Nie Y. Extracellular matrix-based biomaterials for cardiac regeneration and repair. Heart Fail Rev. 2021 Sep;26(5):1231-1248. doi: 10.1007/s10741-020-09953-9
  67. Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018 Oct;15(10):585-600. doi: 10.1038/s41569-018-0036-6
  68. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007 Sep;25(9):1015-24. doi: 10.1038/nbt1327
  69. van Laake LW, Passier R, Monshouwer-Kloots J, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007 Oct;1(1):9-24. doi: 10.1016/j.scr.2007.06.001
  70. Birks EJ, Drakos SG, Patel SR, et al. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020 Nov 24;142(21):2016-2028. doi: 10.1161/CIRCULATIONAHA.120.046415
  71. Uriel N, Burkhoff D, Rich JD, et al. Impact of Hemodynamic Ramp Test-Guided HVAD Speed and Medication Adjustments on Clinical Outcomes. Circ Heart Fail. 2019 Apr;12(4):e006067. doi: 10.1161/CIRCHEARTFAILURE.119.006067
  72. Bruckner BA, Stetson SJ, Farmer JA, et al. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg. 2000 Dec;180(6):498-501; discussion 501-2. doi: 10.1016/s0002-9610(00)00553-5
  73. John KJ, Stone SM, Zhang Y, et al. Application of Cardiogenic Shock Working Group-defined Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) Staging of Cardiogenic Shock to the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Cardiovasc Revasc Med. 2023 Dec:57:82-90. doi: 10.1016/j.carrev.2023.06.019
  74. Zweck E, Thayer KL, Helgestad OKL, et al. Phenotyping Cardiogenic Shock. J Am Heart Assoc. 2021 Jul 20;10(14):e020085. doi: 10.1161/JAHA.120.020085
  75. Meki MH, Miller JM, Mohamed TMA. Heart Slices to Model Cardiac Physiology. Front Pharmacol. 2021 Feb 4:12:617922. doi: 10.3389/fphar.2021.617922
  76. Binanay C, Califf RM, Hasselblad V, et al.; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005 Oct 5;294(13):1625-33. doi: 10.1001/jama.294.13.1625
  77. Garan AR, Kanwar M, Thayer KL, et al. Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality. JACC Heart Fail. 2020 Nov;8(11):903-913. doi: 10.1016/j.jchf.2020.08.012
  78. Kapur NK, Kim RJ, Moses JW, et al. Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial. Am Heart J. 2022 Dec:254:122-132. doi: 10.1016/j.ahj.2022.08.011
  79. Everett KD, Swain L, Reyelt L, et al. Transvalvular Unloading Mitigates Ventricular Injury Due to Venoarterial Extracorporeal Membrane Oxygenation in Acute Myocardial Infarction. JACC Basic Transl Sci. 2023 May 10;8(7):769-780. doi: 10.1016/j.jacbts.2023.01.004
  80. Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol. 1989 Jul;14(1):40-6; discussion 47-8. doi: 10.1016/0735-1097(89)90051-x
  81. Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004 Jul 21;44(2):340-8. doi: 10.1016/j.jacc.2004.03.060
  82. Bilkova D, Motovska Z, Widimsky P, Dvorak J, Lisa L, Budesinsky T. Shock index: a simple clinical parameter for quick mortality risk assessment in acute myocardial infarction. Can J Cardiol. 2011 Nov-Dec;27(6):739-42. doi: 10.1016/j.cjca.2011.07.008
  83. Link A, Pöss J, Rbah R, et al. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J. 2013 Jun;34(22):1651-62. doi: 10.1093/eurheartj/ehs487
DOI: https://doi.org/10.14797/mdcvj.1383 | Journal eISSN: 1947-6108
Language: English
Page range: 64 - 75
Submitted on: Mar 30, 2024
Accepted on: Jun 25, 2024
Published on: Aug 20, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2024 Kevin John, Adnan Khalif, Masaki Tsukashita, Manreet K. Kanwar, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.